INBS Clears Cybersecurity Hurdles, Strengthens FDA 510(k) Package with Cost-Saving Manufacturing Deal
INBS is trading near its 52-week low of $1.577 (11% above the low).
Summary
Intelligent Bio Solutions has resolved all cybersecurity and software review items for its FDA 510(k) submission, a critical de-risking step ahead of the planned H2 2026 filing. The company remediated 100% of medium-risk vulnerabilities and reduced low-risk items from 11 to 2, with independent verification confirming no remaining issues. This follows the July 21 precision testing completion and the June 2 method comparison study initiation, building a comprehensive regulatory package. Additionally, a manufacturing partnership with Syrma Johari MedTech is expected to cut annual production costs by over 40% and improve gross margins by approximately 20 percentage points, strengthening the financial case for U.S. market entry. The 510(k) targets codeine detection as the initial indication, with clearance opening a multi-billion-dollar U.S. drug screening market. Submission remains on track for calendar H2 2026.
At the time of this announcement, INBS was trading at $1.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $1.58 to $24.90. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.